Jasper Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Jasper Therapeutics
JSPR Stock  USD 3.11  0.08  2.64%   
Jasper Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Jasper Therapeutics' valuation are provided below:
Market Capitalization
50.5 M
Earnings Share
(6.05)
There are over one hundred nineteen available fundamental trends for Jasper Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Jasper Therapeutics' regular fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction.
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 8.4 M or Selling General Administrative of 13.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.8. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Jasper Stock
Check out the analysis of Jasper Therapeutics Correlation against competitors.
To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Jasper Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets67.4 M79.9 M42.5 M
Slightly volatile
Other Current Liabilities5.1 M10.1 M2.8 M
Slightly volatile
Total Current Liabilities8.9 M15.2 M4.7 M
Slightly volatile
Other Liabilities2.2 M2.3 M4.6 M
Very volatile
Net Tangible Assets57.6 M32.4 M81 M
Slightly volatile
Warrants69 M71.4 M86.8 M
Slightly volatile
Accounts Payable2.9 M4 M1.5 M
Slightly volatile
Cash60.2 M71.6 M39.6 M
Slightly volatile
Non Current Assets Total4.6 M4.1 M1.9 M
Slightly volatile
Non Currrent Assets Other920.3 K820 K398.3 K
Slightly volatile
Cash And Short Term Investments60.2 M71.6 M39.6 M
Slightly volatile
Common Stock Total Equity2.4 K4.6 K1.4 K
Slightly volatile
Short Term Investments80.1 M90.1 M98.3 M
Slightly volatile
Liabilities And Stockholders Equity66.6 M79.9 M39.9 M
Slightly volatile
Non Current Liabilities Total2.8 M3 M7.6 M
Pretty Stable
Capital Surpluse81.2 M162.3 M45.3 M
Slightly volatile
Other Current Assets4.4 M4.2 M1.2 M
Slightly volatile
Total Liabilities17.6 M18.2 M10.4 M
Slightly volatile
Long Term Investments110.3 M115.4 M101.8 M
Slightly volatile
Total Current Assets62.7 M75.8 M40.6 M
Slightly volatile
Non Current Liabilities Other1.9 M2 M4.1 M
Very volatile
Common Stock2.9 K2 K7.2 K
Slightly volatile
Short and Long Term Debt Total2.8 M1.8 M2 M
Slightly volatile
Property Plant And Equipment Net4.3 M2.9 M2.7 M
Slightly volatile
Long Term Debt10.5 M11.8 M12.9 M
Slightly volatile
Net Receivables213.8 K225 K571.6 K
Slightly volatile
Common Stock Shares Outstanding7.4 M14.6 M4.9 M
Slightly volatile
Long Term Debt Total10.5 M11.8 M12.9 M
Slightly volatile
Capital Lease Obligations2.8 M1.8 M2 M
Slightly volatile
Property Plant And Equipment Gross5.6 M6.7 M3.2 M
Slightly volatile
Capital Stock1.9 K2 K1.5 K
Slightly volatile
Net Working Capital59 M60.6 M30.9 M
Slightly volatile
Property Plant Equipment3.8 M4.1 M2.6 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.8 M
Slightly volatile
Short Term Debt960.2 K1.1 M1.1 M
Pretty Stable

Jasper Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1.4 M3.3 M
Slightly volatile
Selling General Administrative13.1 M20.4 M5.9 M
Slightly volatile
Other Operating Expenses47.7 M76.2 M21.9 M
Slightly volatile
Research Development34.3 M55.8 M15.9 M
Slightly volatile
Total Operating Expenses47.3 M76.2 M21.6 M
Slightly volatile
Cost Of Revenue963.2 K1.4 M346.9 K
Slightly volatile
Net Interest Income4 M5.1 M1.5 M
Slightly volatile
Interest Income4 M5.1 M1.5 M
Slightly volatile
Selling And Marketing Expenses886.4 K997.2 K1.1 M
Slightly volatile

Jasper Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings61.6 K64.8 K963.4 K
Slightly volatile
Stock Based Compensation3.3 M6.6 M1.3 M
Slightly volatile
Begin Period Cash Flow47.4 M87.3 M19.1 M
Slightly volatile
Depreciation775.7 K1.4 M525 K
Slightly volatile
Capital Expenditures524.4 K552 K1.9 M
Slightly volatile
Total Cash From Financing Activities53.2 M47.9 M37.9 M
Slightly volatile
End Period Cash Flow60.6 M72.1 M39.7 M
Slightly volatile
Change To Liabilities442.5 K465.8 K683.3 K
Pretty Stable
Issuance Of Capital Stock59.9 M47.2 M27.8 M
Slightly volatile
Other Cashflows From Investing Activities17.1 K18 K142.3 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio4.85.056130.6746
Slightly volatile
Capex To Depreciation0.380.4024.9311
Slightly volatile
PB Ratio4.85.056130.6746
Slightly volatile
Payables Turnover0.240.34090.1185
Slightly volatile
Cash Per Share4.674.911710.0284
Pretty Stable
Days Payables Outstanding1 K1.1 K17.3 K
Slightly volatile
Income Quality0.660.87840.5742
Slightly volatile
Net Debt To EBITDA0.930.978161.7075
Slightly volatile
Current Ratio8.774.975511.2024
Slightly volatile
Shareholders Equity Per Share4.024.22866.9997
Slightly volatile
Debt To Equity0.02790.02940.1429
Slightly volatile
Capex Per Share0.0360.03781.6149
Slightly volatile
Interest Debt Per Share0.120.12430.548
Pretty Stable
Debt To Assets0.02160.02270.059
Slightly volatile
Price Book Value Ratio4.85.056130.6746
Slightly volatile
Days Of Payables Outstanding1 K1.1 K17.3 K
Slightly volatile
Ebt Per Ebit1.110.93611.0433
Pretty Stable
Effective Tax Rate0.01310.02050.0075
Slightly volatile
Company Equity Multiplier1.681.29551.4033
Pretty Stable
Total Debt To Capitalization0.02710.02860.1219
Slightly volatile
Debt Equity Ratio0.02790.02940.1429
Slightly volatile
Quick Ratio8.774.975511.2024
Slightly volatile
Net Income Per E B T0.780.97950.9634
Slightly volatile
Cash Ratio8.484.701511.0884
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00881.0632
Slightly volatile
Price To Book Ratio4.85.056130.6746
Slightly volatile
Debt Ratio0.02160.02270.059
Slightly volatile
Price Fair Value4.85.056130.6746
Slightly volatile

Jasper Fundamental Market Drivers

Cash And Short Term Investments71.6 M

Jasper Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Jasper Therapeutics Financial Statements

Jasper Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Jasper Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Jasper Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Jasper Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue1.4 M963.2 K

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY